| Bioactivity | Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption. | ||||||||||||
| Invitro | Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells[1]. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase[2]. | ||||||||||||
| In Vivo | Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host[1]. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition[3] | ||||||||||||
| Name | Ipriflavone | ||||||||||||
| CAS | 35212-22-7 | ||||||||||||
| Formula | C18H16O3 | ||||||||||||
| Molar Mass | 280.32 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Iisaki T, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002 Aug 1;100(4):381-7. [2]. Hagiwara H, et al. Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J Biochem. 1999 Jul;126(1):168-73. [3]. Civitelli R, et al. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int. 1995 Mar;56(3):215-9. |